Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Litvinov Anatolij AfiledCriticalLitvinov Anatolij A
Priority to SU762420298ApriorityCriticalpatent/SU1101234A1/en
Application grantedgrantedCritical
Publication of SU1101234A1publicationCriticalpatent/SU1101234A1/en
СПОСОБ ЛЕЧЕНИЯ ДЕСТРУКТИВНОГО ТУБЕРКУЛЕЗА ЛЕГКИХ путем внутрилегочного чрезкожного введени противотуберкулезных средств, отличающ и и с тем, что, с целью сокращени сроков лечени , противотуберкулезные средства ввод т внутри- и паракавернозно 1-2 раза в неделю одномоментно или череду внутри- и паракавернозное введение через каждые 3-4 дн .METHOD FOR TREATING DESTRUCTIVE PULMONARY TUBERCULOSIS percutaneous administration by intrapulmonary antitubercular agents, and featuring, and in that in order to reduce treatment time, antituberculosis agents administered intra- and parakavernozno 1-2 times a week, simultaneously or series of intra- and administration every parakavernoznoe 3-4 days
Description
ii
Claims (1)
СПОСОБ ЛЕЧЕНИЯ ДЕСТРУКТИВНОГО ТУБЕРКУЛЕЗА ЛЕГКИХ путем внутриле гочного чр’езкожного введения противотуберкулезных средств, отличавщ и й с я тем, что, с целью сокращения сроков лечения, противотуберкулезные средства вводят внутри- и паракавернозно 1-2 раза в неделю одномоментно или чередуя внутри- и паракавернозное введение через каждые 3-4 дня.METHOD FOR TREATING DESTRUCTIVE TUBERCULOSIS OF THE LUNGS by intramuscular transdermal administration of anti-tuberculosis drugs, characterized in that, in order to reduce the treatment time, anti-tuberculosis drugs are administered intra- and paracaverno-1-2 times a week simultaneously or alternately intravenously and alternately introduction every 3-4 days.
SU762420298A1976-11-161976-11-16Method of treating destructive pulmonary tuberculosis
SU1101234A1
(en)
New drug, more especially used in geriatrics, in asthenic states in all their forms, in certain respiratory and nervous affections and in rheumatology.
N-(1'-allylpyrrolidinyl2'-methyl)2-methoxy 4,5-azimido benzamide, its pharmaceutically acceptable addition salts with acids and methods for its preparation